within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC23_Olokizumab;

model Olokizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.083333333333333e-09,
    adminDuration = 600,
    adminMass = 64 / 1000000,
    adminCount = 1,
    Vd = 0.0045,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0027,
    k12 = 3.240740740740741e-09,
    k21 = 3.240740740740741e-09);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Olokizumab</td></tr><tr><td>ATC code:</td><td>L04AC23</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>64</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>4.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.18</td><td>L/day</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Olokizumab is a humanized monoclonal antibody targeting interleukin-6 (IL-6), used for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to disease-modifying antirheumatic drugs (DMARDs). It was approved in Russia in 2020 for rheumatoid arthritis and is under clinical development elsewhere.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for olokizumab in adult patients with rheumatoid arthritis based on typical monoclonal antibody PK behavior and limited published clinical data.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AC23 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Olokizumab;
